Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ILP101-Inhale
- Development stage
- Preclinical
- Lead developer
- Ilya Pharma
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies
- Administration
- Inhalation
01
Overview
ILP101-Inhale is an investigational gene therapy developed by Ilya Pharma for the treatment of cystic fibrosis. It utilizes a proprietary platform consisting of genetically modified *Lactobacillus reuteri* bacteria engineered to express and deliver the human chemokine CXCL17 directly to the lungs via inhalation. CXCL17 is a mucosal chemokine that binds to the CXCR4 receptor and plays a role in modulating the pulmonary immune environment. By acting as on-site mini-bioreactors, the bacteria produce therapeutic quantities of the chemokine to address the underlying immune dysfunction in cystic fibrosis. The therapy is classified as an advanced therapy medicinal product (ATMP) by the European Medicines Agency and as a low-risk candidate under the gene therapy umbrella by the FDA.
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)CXCL17
Beyond the preview
Go deeper on ILP101-Inhale.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ILP101-Inhale.